Dr. Peihua Lu
MD, PhD, Board-Certified Hematology & Oncology (USA)
Medical Executive President, Lu Daopei Hospital
corporate_fareLu Daopei Hospital, Beijing, China
Peihua Lu
MD, PhD, Board-Certified Hematology & Oncology (USA)
CancerFax can coordinate medical-report review, case preparation, and consultation support for international patients seeking access to Dr. Lu and the Lu Daopei clinical programmes, subject to case acceptance and hospital availability.
Why Consider Dr. Peihua (Peggy) Lu?
Dr. Peggy Lu combines American board-certified haematology expertise with decades of clinical leadership at one of Asia's most active CAR-T and bone marrow transplantation centres, making her a highly sought-after specialist for patients with relapsed, refractory, or high-risk blood cancers.
Areas of Specialisation
Expert in haematologic malignancies, cellular immunotherapy, and stem cell transplantation
CAR-T Cell Immunotherapy
Pioneering cellular immunotherapy for relapsed and refractory haematologic malignancies using multiple CAR-T targets.
- arrow_rightCAR-T therapy for relapsed/refractory B-cell acute lymphoblastic leukaemia (B-ALL)
- arrow_rightCD28 and 4-1BB co-stimulatory domain platforms evaluated in clinical trials
- arrow_rightIntegration of CD19 CAR-T with allogeneic stem cell transplantation
- arrow_rightNanobody-based BCMA CAR-T for relapsed/refractory multiple myeloma
- arrow_rightHigh response rates including extramedullary lesions and high-risk cytogenetics
- arrow_rightClinical trial leadership at Beijing Lu Daopei Hospital (NCT04447573)
- arrow_rightFirst-in-human phase 1 naturally selected CD7 CAR-T for T-ALL and T-LBL (Blood, 2022)
- arrow_rightCAR-T therapy for CD7-positive T-cell acute lymphoblastic leukaemia
- arrow_rightCD7 CAR-T for mixed phenotype acute leukaemia (MPAL) and CNS involvement
Leukaemia Management
Comprehensive diagnosis and treatment of acute and chronic leukaemias, including high-risk and relapsed presentations.
- arrow_rightAcute lymphoblastic leukaemia (ALL) — B-cell and T-cell subtypes
- arrow_rightAcute myeloid leukaemia (AML) and mixed phenotype acute leukaemia (MPAL)
- arrow_rightRelapsed and refractory leukaemia using cellular immunotherapy and transplantation
- arrow_rightChronic myeloid leukaemia (CML) management
- arrow_rightChronic lymphocytic leukaemia (CLL) diagnosis and systemic treatment
- arrow_rightMyeloproliferative neoplasms (MPN) — acute and chronic forms
Lymphoma & Multiple Myeloma
Specialised care for B-cell and T-cell lymphomas and plasma cell disorders including relapsed and high-risk disease.
- arrow_rightDiffuse large B-cell lymphoma (DLBCL) and relapsed/refractory NHL
- arrow_rightT-cell lymphoma, NK/T-cell lymphoma, and lymphoblastic lymphoma
- arrow_rightCAR-T integration for refractory lymphoma (SL1904B trial, NCT04447547)
- arrow_rightBCMA CAR-T therapy for relapsed/refractory multiple myeloma
- arrow_rightHigh-risk myeloma and plasma cell leukaemia treatment
- arrow_rightDirector, Lymphoma and Multiple Myeloma Centre, Lu Daopei Hospital
Haematopoietic Stem Cell Transplantation
Bone marrow and stem cell transplantation for haematologic malignancies and bone marrow failure disorders.
- arrow_rightHaploidentical stem cell transplantation for high-risk leukaemia
- arrow_rightMatched sibling and unrelated donor transplantation
- arrow_rightCAR-T bridging to allogeneic SCT — Lu Daopei's proprietary protocol
- arrow_rightSevere aplastic anaemia — diagnosis and transplantation strategies
- arrow_rightMyelodysplastic syndromes (MDS) management and transplantation
- arrow_rightMyeloproliferative neoplasms and related conditions
Procedures & Clinical Programmes
Advanced haematology, cellular therapy, and transplantation services
CAR-T Cell Immunotherapy
Medical OncologyAdministration and clinical trial oversight of CD19, BCMA, and CD7-targeted CAR-T programmes for relapsed and refractory haematologic malignancies.
Haematopoietic Stem Cell Transplantation
TransplantFull-spectrum bone marrow and stem cell transplantation for haematologic malignancies, bone marrow failure, and high-risk disease presentations.
Systemic Treatment of Blood Cancers
Medical OncologyComprehensive systemic therapy planning for leukaemia, lymphoma, multiple myeloma, and related haematologic conditions.
Complex Disease Assessment & Second Opinion
Second OpinionInternational second-opinion consultations and multidisciplinary case review for complex, relapsed, or refractory haematologic malignancies.
Monitoring & Follow-Up
MonitoringPost-CAR-T and post-transplant monitoring, disease surveillance, and management of treatment-related complications.
Research & Publications
Landmark contributions in CAR-T cell therapy, haematology, and translational research
Lu Daopei Hospital maintains active CAR-T clinical trials. CancerFax can help eligible patients explore trial access as part of case coordination, subject to enrolment criteria and physician review.
Education & Training
Dr. Peihua (Peggy) Lu holds a Doctor of Medicine degree from Peking University Medical School and completed advanced clinical training in haematology and oncology at prestigious institutions in the United States, including residency at the University of Nebraska Medical Center and fellowship at Stanford University Medical Center.
Clinical Experience
Dr. Lu has spent her career building and leading one of the world's most active haematology and cellular therapy programmes. Following advanced training in the United States, she returned to China to help establish Lu Daopei Hospital as a globally recognised centre for CAR-T therapy, bone marrow transplantation, and treatment of complex blood cancers.
Languages & International
Dr. Peihua (Peggy) Lu consults in the following languages.
CancerFax can coordinate professional medical interpreter support for international patients whose primary language is not English or Mandarin.
CancerFax can coordinate professional medical interpreter support for international patients consulting in other languages.
How CancerFax Helps You Access Dr. Peihua Lu
CancerFax is a specialist cancer patient-navigation platform. We help international patients prepare structured medical summaries, assess treatment eligibility, and connect directly with Dr. Peihua Lu's team — with full coordination from initial inquiry to consultation.
Medical Report Review
Free review of your pathology results, imaging, molecular profiling, and treatment history — prepared as a structured clinical summary for Dr. Peihua Lu's team.
Treatment Eligibility Screening
CancerFax screens your case for eligibility for treatments and clinical programmes available through Dr. Peihua Lu before you travel, so you arrive with a clear pathway.
Case Submission
We coordinate direct case submission to Dr. Peihua Lu's department, including all documentation required for clinical review and appointment scheduling.
Appointment & Consultation Coordination
CancerFax manages appointment scheduling with Dr. Peihua Lu's team, confirming availability and aligning timelines with your travel plans.
Travel, Visa & Logistics Support
We prepare visa invitation letters, provide hospital-proximity accommodation guidance, and coordinate airport transfers for international patients.
Follow-Up & Continuity of Care
After your consultation or treatment, CancerFax facilitates communication between Dr. Peihua Lu's team and your home oncologist for seamless post-treatment follow-up.
Frequently Asked Questions About Dr. Peihua (Peggy) Lu
Dr. Peihua (Peggy) Lu, MD, PhD, is one of China's foremost haematologist-oncologists and a globally recognised expert in CAR-T cell therapy, haematopoietic stem cell transplantation, and blood cancer management. She serves as Medical Executive President of Lu Daopei Hospital and Lu Daopei Institute of Hematology in Beijing, China. She is American Board Certified in Haematology and Oncology and has completed fellowship training at Stanford University Medical Center.
Dr. Lu specialises in the full spectrum of haematologic malignancies, including acute lymphoblastic leukaemia (ALL), acute myeloid leukaemia (AML), chronic myeloid leukaemia (CML), chronic lymphocytic leukaemia (CLL), diffuse large B-cell lymphoma (DLBCL), T-cell and NK/T-cell lymphoma, multiple myeloma, aplastic anaemia, myelodysplastic syndromes (MDS), and myeloproliferative neoplasms. She has particular expertise in relapsed and refractory haematologic malignancies where standard therapies have failed.
Dr. Lu has led CAR-T clinical programmes at Lu Daopei Hospital since 2015. She has been Principal Investigator on trials using CD19-targeted CAR-T for B-cell leukaemia and lymphoma, BCMA-targeted CAR-T for multiple myeloma, and CD7-targeted CAR-T for T-cell leukaemia and lymphoma — including a landmark first-in-human phase 1 study published in Blood (2022). The hospital also integrates CAR-T therapy with haploidentical stem cell transplantation to improve long-term outcomes.
Lu Daopei Hospital regularly treats international patients from the Middle East, Africa, Russia, Southeast Asia, and South Asia. CancerFax can assist international patients by coordinating medical-report review, case preparation, and submission to Dr. Lu's team at Lu Daopei Hospital, subject to case acceptance and clinical eligibility. Contact CancerFax to begin the process.
International patients can submit a second-opinion request through CancerFax. The CancerFax team will review the submitted medical documents — including pathology reports, bone marrow biopsy results, imaging, molecular findings, and treatment history — and coordinate the case submission with Lu Daopei Hospital. The format and availability of the consultation depend on Dr. Lu's clinical schedule and the hospital's case review process.
Lu Daopei Hospital is one of the world's most active centres for CAR-T cell therapy and haematopoietic stem cell transplantation. The hospital has treated over 500 patients in CAR-T clinical trials and has reported complete remission rates of approximately 90% in selected leukaemia cohorts. For patients with relapsed or refractory blood cancers who have exhausted standard treatment options in their home country, Lu Daopei may offer access to clinical-grade cellular therapies and active clinical trials not available elsewhere. CancerFax can help assess eligibility and coordinate access.
To request a consultation with Dr. Lu, submit your medical reports through CancerFax — including diagnosis documents, pathology results, bone marrow or biopsy reports, imaging studies, and a summary of previous treatments. The CancerFax team will review your case, prepare the necessary documentation, and coordinate the next steps with Lu Daopei Hospital on your behalf, subject to clinical availability and case acceptance criteria.
Connect with Peihua Lu Today
Share your medical reports for a free preliminary review. Our patient coordinators will help you understand your options and arrange a direct consultation.
Medical Disclaimer: Information on this page is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making any medical decisions.